

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.			
10/737,014	12/16/2003	Abubakr Aslamkhan	2191US	4518			
22881 73	590 06/23/2006		EXAM	EXAMINER			
MATT CATL	-	LILLING, H	LILLING, HERBERT J				
SENIOR COU	NSEL CE PAHARMACEUTIC	ART UNIT	PAPER NUMBER				
FIVE SCIENC		1651					
NEW HAVEN	, CT 06511	DATE MAILED: 06/23/2006					

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Applicati	on No.	Applicant(s)				
		10/737,0	14	ASLAMKHAN ET AL.				
		Examine		Art Unit				
		HERBER	Γ J. LILLING	1651				
Period fo	The MAILING DATE of this communication Reply	on appears on th	e cover sheet with the c	orrespondence ad	ddress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1) 又	Responsive to communication(s) filed on	12-16-2003 (CF	RF)					
-	This action is FINAL . 2b)⊠ This action is non-final.							
,—	Since this application is in condition for a			secution as to the	e merits is			
,	closed in accordance with the practice up							
Disposition of Claims								
4)⊠	Claim(s) 1-40 is/are pending in the applic	cation						
•	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
·								
	Claim(s) is/are objected to.							
·	Claim(s) <u>1-40</u> are subject to restriction as	nd/or election re	quirement.					
	• • •	1101 01001011 10	quii orriorra					
_	on Papers							
•	The specification is objected to by the Ex			_				
10)⊠	The drawing(s) filed on <u>16 December 200</u>	_	·	-	niner.			
	Applicant may not request that any objection							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority ι	ınder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice 3) Information	e of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-9 mation Disclosure Statement(s) (PTO-1449 or PTO or No(s)/Mail Date	•	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate	⁻ O-152)			

 Receipt is acknowledged of the CRF, which has been approved by STIC on December 30, 2003.

2. This application contains claims directed to the following patentably distinct species:

Whereby method for identifying inhibitors of a chlorophyll synthase (CS) enzyme, comprising: a) incubating a CS polypeptide with a chlorophyllide and a phospholipid substrate:

- a. in the presence and absence of a test compound under conditions suitable for CS activity;
- b. in the presence of a water-soluble dye that absorbs in the range of one or both of the excitation and emission wavelength ranges of the chlorophyllide substrate, and in the presence and absence of a test compound under conditions suitable for CS activity;
- c. a method for concurrently testing a plurality of compounds as inhibitors of a chlorophyll synthase (CS) enzyme, comprising: a) incubating a plurality of test compounds in a multi-well format, individually or in mixtures, with a CS polypeptide and a chlorophyllide and phospholipid substrate under conditions suitable for CS activity and b) incubating in at least one of the wells the CS polypeptide and the substrates under conditions suitable for CS activity in the absence of a test compound;

Art Unit: 1651

- d. a method for concurrently testing a plurality of compounds as inhibitors of a chlorophyll synthase (CS) enzyme, comprising incubating a plurality of test compounds in a multi-well format, individually or in mixtures, with a CS polypeptide and a chlorophyllide and phospholipid substrate under conditions suitable for CS activity, and with a water-soluble dye that absorbs in the range of one or both of the excitation and emission wavelength ranges of the chlorophyllide substrate.
- 3. The species are independent or distinct because each of the above procedures involves different testing and process steps.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claim is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

4. Applicant is advised that the reply to this requirement to be complete must include

Page 4

(i) an election of a species to be examined even though the requirement be traversed (37 CFR 1.143)

<u>and</u>

(ii) identification of the claims encompassing the elected invention.

The election of a species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103 (a) of the other invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected species, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/737,014

Art Unit: 1651

6. The specification has not been checked to the extent

Page 5

necessary to determine the presence of all possible minor errors. Applicant's

cooperation is requested in correcting any errors of which applicant may become aware

in the specification.

7. Any inquiry concerning this communication or earlier communications from

the examiner should be directed to **Examiner Lilling whose telephone number is 571-272-0918** and **Fax Number** is (703) 872-9306 or SPE Michael Wityshyn whose telephone number is 571-272-0926. Examiner can be reached Monday-Thursday from about 5:30 A.M. to about 3:00 P.M. Any inquiry of a general nature or relating to the

status of this application should be directed to the Group receptionist whose telephone

number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see

http://portal.uspto.gov/external/portal/pair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-

9197 (toll-free).

H.J.Lilling: HJL (571) 272-0918 Art Unit **1651**

June 19, 2006

Dr. Herbert J. Lilling Primary Examiner

Group 1600 Art Unit 1651